ClearPoint Neuro, Inc. (CLPT) Fair Value 2026

CLPT · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.5 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (31/100)

Quick Summary — As of 2026-08-28, ClearPoint Neuro, Inc. (CLPT) trades at $15.55. QOC: 6.5/10. Value Trap Risk: 31/100 (LOW). 0/13 models active.

Key Facts

Ticker
CLPT
Price
$15.55
Quality Score
6.5/10
Value Trap Risk
31/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give CLPT?

0 Intrinsic Value Models vs. Current Price ($15.55)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is ClearPoint Neuro, Inc. (CLPT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, ClearPoint Neuro, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About CLPT?

0 of 13 models are currently active for CLPT. See which stocks rank higher →

How Does CLPT Rank in Medical Devices?

Among 159 Medical Devices stocks, CLPT ranks #70 by Quality of Company score. CirclFi's QOC score of 6.5/10 evaluates 32 fundamental signals. A score of 6.5 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

Within the Medical Devices space, ClearPoint Neuro, Inc. competes in an environment where FDA approval probability often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is CLPT a Value Trap?

CirclFi's Value Trap algorithm assigns CLPT a score of 31/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for ClearPoint Neuro, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, ClearPoint Neuro, Inc. is rated at 6.5/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CLPT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy ClearPoint Neuro, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

TMCITreace Medical Concepts, Inc.QOC 6.5RXSTRxSight, Inc.QOC 6.5TELATELA Bio, Inc.QOC 6.5TNDMTandem Diabetes Care, Inc.QOC 6.5SERASera Prognostics, Inc.QOC 6.6BFLYButterfly Network, Inc.QOC 6.4PACBPacific Biosciences of California, Inc.QOC 5.6LUDGLudwig Enterprises, Inc.QOC 3.7GEHCGE HealthCare Technologies Inc.QOC 7.9IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: TMCI · RXST · TELA · TNDM · SERA · BFLY · PACB · LUDG · GEHC · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to CLPT?

7 companies across all industries closest to CLPT’s Quality of Company score of 6.5/10.

RCATRed Cat Holdings, Inc.QOC 6.5NAVINavient CorporationQOC 6.5APDAir Products and Chemicals, Inc.QOC 6.5NAIINatural Alternatives International, Inc.QOC 6.5ZIPZipRecruiter, Inc.QOC 6.5STEMStem, Inc.QOC 6.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RCAT · NAVI · APD · NAII · ZIP · STEM · NVDA

Where Does CLPT Sit in CirclFi's Medical Devices Rankings?

CLPT is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About ClearPoint Neuro, Inc.’s Valuation?

What is ClearPoint Neuro, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for ClearPoint Neuro, Inc. (CLPT). The Quality of Company score is 6.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CLPT overvalued or undervalued right now?

At $15.55, 0 of 0 active models suggest CLPT may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits ClearPoint Neuro, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 6.5 mean for CLPT?

ClearPoint Neuro, Inc.'s QOC of 6.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CLPT?

CirclFi analyzes CLPT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is CLPT a value trap in 2026?

ClearPoint Neuro, Inc.'s Value Trap score is 31/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns ClearPoint Neuro, Inc. (CLPT) a Quality of Company score of 6.5/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/CLPT/ · Methodology
Primary sources for this CLPT valuation
  • Financial statements: ClearPoint Neuro, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001285550) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CLPT as of ; valuations recomputed .